Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 7/20 | 0.46 |
| ▸ | RARB | P10826 | 7/20 | 0.46 |
| ▸ | RARG | P13631 | 6/20 | 0.46 |
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | RXRA | P19793 | 5/20 | 0.36 |
| ▸ | RXRB | P28702 | 3/20 | 0.36 |
| ▸ | KIF11 | P52732 | 3/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27395129 | 0.86 | RARB (0.57) | RARARARBRARGRXRAJAK2 | |
| SCHEMBL27395186 | 0.85 | RARA (0.54) | RARARARBRARGRXRAJAK2 | |
| SCHEMBL31419468 | 0.84 | CNR1 (0.55) | CNR1RXRARXRBKIF11SYK | |
| SCHEMBL26306083 | 0.83 | RARA (0.56) | RARARARBRARGRXRA | |
| SCHEMBL31027984 | 0.82 | CNR1 (0.52) | CNR1RXRARXRBKIF11SYK | |
| SCHEMBL26306822 | 0.81 | RARB (0.52) | RARARARBRARGRXRASYK | |
| SCHEMBL27395073 | 0.80 | RARA (0.55) | RARARARBRARGRXRA | |
| SCHEMBL25491121 | 0.80 | RARA (0.58) | RARARARBRARGRXRA | |
| SCHEMBL27395178 | 0.80 | RARA (0.50) | RARARARBRARGRXRAJAK2 | |
| SCHEMBL27395220 | 0.80 | RARB (0.47) | RARARARBRARGRXRAJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4335855-B1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND DIAGNOSTIC COMPOSITION INCLUDING THE HETEROCYCLIC COMPOUND | SAMSUNG ELECTRONICS CO LTD (KR) | 2025-06-04 | — | — | EP | disclosed |
| US-20240116955-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND DIAGNOSTIC COMPOSITION INCLUDING THE HETEROCYCLIC COMPOUND | SAMSUNG DISPLAY CO., LTD. (KR) | 2024-04-11 | — | — | US | disclosed |
| EP-4335855-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND DIAGNOSTIC COMPOSITION INCLUDING THE HETEROCYCLIC COMPOUND | Samsung Electronics Co., Ltd. (KR) | 2024-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116955-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND DIAGNOSTIC COMPOSITION INCLUDING THE HETEROCYCLIC COMPOUND | ORC3, ODC1, DDX41 | RARA 2892/4885RARB 3247/4885RARG 3254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.